Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

BACKGROUND: Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties. The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to progression of patients with advanced hepatocellular carcinoma (HCC). The aim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Lee, Sae Hwan, Song, Il Han, Noh, Ran, Kang, Ha Yan, Kim, Suk Bae, Ko, Soon Young, Lee, Eoum Seok, Kim, Seok Hyun, Lee, Byung Seok, Kim, An Na, Chae, Hee Bok, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Lee, Jae Dong, Lee, Heon Young
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4403976/
https://ncbi.nlm.nih.gov/pubmed/25885683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1273-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados